Novartis Buys Tourmaline Bio: A $1.4 Billion Deal

Novartis is set to acquire Tourmaline Bio for $1.4 billion! This acquisition is expected to finalize in Q4 and signals a strategic move by Novartis to expand its presence in the biopharmaceutical market. Industry experts predict this could lead to further consolidation in the pharmaceutical world. Hosted on Acast. See acast.com/privacy for more information.